STOP THE WAR! Let’s support Ukraine Together

Hamilton Lane Alliance Holdings I, Inc. (HLAHU) Prices Upsized $240M IPO

ipo
IPO
arclight---proterra

ArcLight Clean Transition Corp. (ACTC) to Combine with Proterra in $1.6Bn Deal

ArcLight Clean Transition Corp. (NASDAQ:ACTC) has entered into a definitive combination agreement with electric vehicle (EV) manufacturer Proterra in a deal giving the merged entity an enterprise value of $1.6 billion. Proterra designs and manufactures zero-emission electric buses as well as battery and drivetrain components for commercial electric vehicles like construction equipment and heavy trucks.
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.
IPO
ipo
IPO
SPAC pricing
RUMORS

Churchill Capital Corporation IV (CCIV) Reportedly in Talks for Merger with Lucid Motors

Churchill Capital Corporation IV is reportedly in talks to combine with electric vehicle (EV) manufacturer Lucid Motors, according to Bloomberg. Lucid reportedly may be valued at up to $15 billion, which could make it the biggest SPAC combination in the EV space and near the top of the list of overall SPAC deals (Gores IV is
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
IPO-Pricing
VPC-Impact-Bakkt-logo

VPC Impact Acquisition Holdings (VIH) to Combine with Bakkt in $2.1Bn Deal

VPC Impact Acquisition Holdings (NASDAQ:VIH) announced this morning that it has entered into a definitive combination agreement with digital asset marketplace Bakkt Holdings giving the merged entity an enterprise value of $2.1 billion. Bakkt provides a platform for consumers to use cryptocurrencies for payments and retail transactions as well as other digital assets like loyalty
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.
SPAC-Terms-Tracker
IPO
switchback-ii
gx-celularity-2

GX Acquisition Corp. (GXGX) to Combine with Celularity in $1.3Bn Deal

GX Acquisition Corp. (NASDAQ:GXGX) announced this morning that it has entered into a definitive merger agreement with clinical stage biotech firm Celularity that would give the combined entity a pro forma enterprise value of $1.29 billion. Celularity has four active and enrolling clinical trials using placental-derived cells to target multiple ailments including several cancer types
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.
SPAC pricing
IPO
ipo
IPO-Pricing
IPO